Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas.
Once thought to be rare, oligodendroglial tumors might actually represent up to 25% of primary glial neoplasms. In recent years, the histologic criteria for the diagnosis of oligodendroglioma have been broadened to include most small cell, monomorphic glial neoplasms. These refinements have led to an increased recognition of oligodendroglial neoplasms, but uniform definitions of pure versus mixed oligodendroglioma as well as the criteria for high-grade (anaplastic) versus low-grade tumors remain elusive. From a prognostic standpoint, the presence of an oligodendroglial component in a malignant glioma predicts longer survivals times for patients treated with surgery, and radiation therapy with or without chemotherapy. High rates of response to PCV (procarbazine, CCNU and Vincristine) chemotherapy also have been noted among patients with anaplastic oligodendroglial neoplasms. Ongoing prospective trials seek to clarify the role of PCV chemotherapy when added to radiation therapy and surgery. In addition, the role of molecular markers as diagnostic aides and guides to therapy and prognosis are being explored for patients with pure and mixed anaplastic oligodendroglial tumors.
Bauman
G S
GS
Department of Oncology, Unviersity of Western Ontario, London, Ontario, Canada.
Cairncross
J G
JG
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D001932:Brain Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D005910:Glioma / Q000628:therapy*; D006801:Humans; D008130:Lomustine; D009367:Neoplasm Staging; D009837:Oligodendroglioma / Q000628:therapy*; D011344:Procarbazine; D011379:Prognosis; D016896:Treatment Outcome; D014750:Vincristine
D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine